3-89413153-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_005233.6(EPHA3):c.1775G>A(p.Gly592Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000447 in 1,610,990 control chromosomes in the GnomAD database, including 2 homozygotes. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000046 ( 2 hom. )
Consequence
EPHA3
NM_005233.6 missense
NM_005233.6 missense
Scores
4
9
6
Clinical Significance
Conservation
PhyloP100: 9.96
Genes affected
EPHA3 (HGNC:3387): (EPH receptor A3) This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Two alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
EPHA3 | NM_005233.6 | c.1775G>A | p.Gly592Asp | missense_variant | 10/17 | ENST00000336596.7 | |
EPHA3 | NM_001410778.1 | c.1775G>A | p.Gly592Asp | missense_variant | 10/17 | ||
EPHA3 | XM_005264715.4 | c.1772G>A | p.Gly591Asp | missense_variant | 10/17 | ||
EPHA3 | XM_047447673.1 | c.1772G>A | p.Gly591Asp | missense_variant | 10/17 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
EPHA3 | ENST00000336596.7 | c.1775G>A | p.Gly592Asp | missense_variant | 10/17 | 1 | NM_005233.6 | P1 | |
EPHA3 | ENST00000494014.1 | c.1775G>A | p.Gly592Asp | missense_variant | 10/17 | 1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000330 AC: 5AN: 151388Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
5
AN:
151388
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000144 AC: 36AN: 250438Hom.: 1 AF XY: 0.000155 AC XY: 21AN XY: 135320
GnomAD3 exomes
AF:
AC:
36
AN:
250438
Hom.:
AF XY:
AC XY:
21
AN XY:
135320
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000459 AC: 67AN: 1459484Hom.: 2 Cov.: 31 AF XY: 0.0000523 AC XY: 38AN XY: 726098
GnomAD4 exome
AF:
AC:
67
AN:
1459484
Hom.:
Cov.:
31
AF XY:
AC XY:
38
AN XY:
726098
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000330 AC: 5AN: 151506Hom.: 0 Cov.: 32 AF XY: 0.0000541 AC XY: 4AN XY: 74004
GnomAD4 genome
?
AF:
AC:
5
AN:
151506
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74004
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
?
AF:
AC:
19
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 17, 2024 | The c.1775G>A (p.G592D) alteration is located in exon 10 (coding exon 10) of the EPHA3 gene. This alteration results from a G to A substitution at nucleotide position 1775, causing the glycine (G) at amino acid position 592 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
Cadd
Pathogenic
Dann
Uncertain
DEOGEN2
Benign
T;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D
M_CAP
Benign
D
MetaRNN
Uncertain
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.
MutationTaster
Benign
D;D
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D
REVEL
Uncertain
Sift
Uncertain
D;D
Sift4G
Benign
T;T
Polyphen
D;.
Vest4
MutPred
Gain of ubiquitination at K589 (P = 0.0605);Gain of ubiquitination at K589 (P = 0.0605);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at